About Evolva
Evolva is a company based in Reinach (Switzerland) founded in 2004 was acquired by Lallemand in November 2023. Evolva has raised $67.27 million across 8 funding rounds from investors including Lallemand, European Union and Nice & Green. The company has 7 employees as of March 26, 2024. Evolva has completed 3 acquisitions, including Allylix, ArpIda and Prosarix. Evolva offers products and services including Flavour and Fragrance Products and Newsletter Subscription. Evolva operates in a competitive market with competitors including General Mills, Conagra Brands, Sweet Karam Coffee, Godrej Agrovet and Keventer, among others.
- Headquarter Reinach, Switzerland
- Employees 7 as on 26 Mar, 2024
- Stage Public
-
Sectors
Consumer
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evolva Biotech Private Limited
- Date of Incorporation 07 Feb, 2005
- Jurisdiction Chennai, Tamil Nadu, India
-
Annual Revenue
$783.47 (USD)-98.21as on Mar 31, 2020
-
Net Profit
-$3.88 K (USD)99.53as on Mar 31, 2020
-
EBITDA
-$4.66 K (USD)99.4as on Mar 31, 2020
-
Total Equity Funding
$67.27 M (USD)
in 8 rounds
-
Latest Funding Round
$12.69 M (USD), Post-IPO
Jan 11, 2022
-
Investors
Lallemand
& 12 more
-
Employee Count
7
as on Mar 26, 2024
-
Investments & Acquisitions
Allylix
& 2 more
-
Acquired by
Lallemand
(Nov 21, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evolva
Evolva offers a comprehensive portfolio of products and services, including Flavour and Fragrance Products and Newsletter Subscription.
Sustainable ingredients for food and beverage applications
Platform for updates on products and industry news
People of Evolva
Unlock access to complete
Unlock access to complete
Funding Insights of Evolva
Evolva has successfully raised a total of $67.27M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $12.69 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evolva
Evolva has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Lallemand, European Union and Nice & Green.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Investments are made in early-stage healthcare startups.
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked |
Investor details for Evolva
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evolva
Evolva has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Allylix, ArpIda and Prosarix.
Investment portfolio details for Evolva
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Computational drug discovery company with proprietary platform for small molecule screening and design
|
Locked | Locked | 2006 | Locked | |
|
Flavoring ingredients are produced from plants via yeast fermentation.
|
Locked | Locked | 2002 | Locked | |
|
Drugs for treating microbial resistance are developed by the company.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Evolva
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Evolva
Detailed financials for Evolva
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evolva Comparisons
Peer comparison for Evolva
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evolva
Evolva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as General Mills, Conagra Brands, Sweet Karam Coffee, Godrej Agrovet and Keventer, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Multi-category food products are produced and distributed globally.
|
|
| Locked | Locked | Locked |
Vertically integrated company in manufacturing and supply of value-added meat and food products
|
|
| Locked | Locked | Locked |
Dry snacks and coffee are manufactured and distributed.
|
|
| Locked | Locked | Locked |
Diversified crop protection solutions are provided to farmers.
|
|
| Locked | Locked | Locked |
Multi-category food and beverage products are provided by Keventer.
|
|
| Locked | Locked | Locked |
AI-powered technology is developed for food product innovation and development.
|
Detailed competitors of Evolva
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evolva
Complete news archive for Evolva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evolva
Evolva was founded in 2004.
Evolva is headquartered in Reinach, Switzerland. It is registered at Reinach, Basel-landschaft, Switzerland.
Murali Panchapagesa is the current CEO of Evolva.
Evolva is a funded company, having raised a total of $67.27M across 8 funding rounds to date.
As of Mar 26, 2024, the latest employee count at Evolva is 7.
Annual revenue of Evolva is $783.47 as on Mar 31, 2020.
The company was founded in 2004 in Reinach, Switzerland, and operates in the biotechnology sector focused on ingredients for food, beverages, and healthcare. Small molecule compounds are created and optimized through biosynthetic and evolutionary technologies, with production routes developed for sustainability. Operations emphasize natural and functional solutions, serving global markets in these industries.
Evolva's top competitors include Sweet Karam Coffee, Kraft Heinz Company and General Mills.
Evolva offers Flavour and Fragrance Products and Newsletter Subscription.
Evolva has 13 investors. Key investors include Lallemand, European Union, Nice & Green, VERAISON Capital, and Wellington Partners Venture Capital.